Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

Description: Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

Summary

‘Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
- The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline
therapeutics
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction

Bile Duct Cancer (Cholangiocarcinoma) Overview

Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance

Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies

Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment

Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corporation, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corporation, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co., Ltd., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Pipeline by</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halozyme Therapeutics, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Innopharmax Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Komipharm International Co., Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Loxo Oncology, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Mebiopharm Co., Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>MedImmune, LLC</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Merrimack Pharmaceuticals, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>NanoCarrier Co., Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>NormOxys, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>NuCana BioMed Limited</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>OncoTherapy Science, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Ono Pharmaceutical Co., Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Panacea Pharmaceuticals, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>PCI Biotech Holding ASA</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Pfizer Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Plexxikon Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Provecs Medical GmbH</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Puma Biotechnology, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>RedHill Biopharma Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Senhwa Biosciences, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Sun Pharma Advanced Research Company Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Taiwan Liposome Company, Ltd.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>tella Inc</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Threshold Pharmaceuticals, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
<tr>
<td>VasGene Therapeutics, Inc.</td>
<td>Bile Duct Cancer (Cholangiocarcinoma)</td>
<td>H1 2016</td>
</tr>
</tbody>
</table>

Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3774189/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3774189/
Office Code: SCD23GC3

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Format</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 2000</td>
</tr>
<tr>
<td></td>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 4000</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) -</td>
<td>USD 6000</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]

First Name: ____________________________ Last Name: ____________________________

Email Address: * ____________________________

Job Title: ____________________________

Organisation: ____________________________

Address: ____________________________

City: ____________________________

Postal / Zip Code: ____________________________

Country: ____________________________

Phone Number: ____________________________

Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World